For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant revenue | - | 0 | - | 57,480 |
| Research and development | 333,334 | 295,260 | 345,861 | 867,345 |
| General and administrative | 914,569 | 825,229 | 929,746 | 990,863 |
| Total operating expenses | 1,247,903 | 1,120,489 | 1,275,607 | 1,858,208 |
| Total operating loss | -1,247,903 | -1,120,489 | -1,275,607 | -1,800,728 |
| Interest expense | - | -47,323 | -48,022 | -51,353 |
| Research and development credit | - | - | - | 0 |
| Total other income (expense), net | - | -47,323 | -48,022 | - |
| Interest expense | 53,046 | - | - | - |
| Net loss | -1,300,949 | -1,167,812 | -1,323,629 | -1,852,081 |
| Net loss attributable to noncontrolling interest | -10,495 | -2,770 | -12,348 | -37,661 |
| Net loss attributable to common stockholders | -1,290,454 | -1,165,042 | -1,311,281 | -1,814,420 |
| Basic EPS | 0 | -0.003 | 0 | 0 |
| Diluted EPS | 0 | -0.003 | 0 | 0 |
| Basic Average Shares | 420,279,879 | 420,279,879 | 420,279,879 | 420,279,879 |
| Diluted Average Shares | 420,279,879 | 420,279,879 | 420,279,879 | 420,279,879 |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)